+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anamorelin"

Ghrelin receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Ghrelin receptor agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020 - Product Thumbnail Image

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 87 Pages
  • Global
From
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 65 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Anamorelin is a drug used to treat endocrine and metabolic disorders. It is a ghrelin agonist, meaning it stimulates the release of growth hormone from the pituitary gland. Anamorelin is used to treat cachexia, a condition characterized by muscle wasting and weight loss, which is often seen in patients with cancer or chronic kidney disease. It is also used to treat growth hormone deficiency in adults. Anamorelin is available in tablet form and is taken orally once daily. It is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea. The anamorelin market is a growing one, with many companies developing and marketing the drug. Some of these companies include Helsinn Healthcare, Eisai Co., Ltd., and Novartis AG. Show Less Read more